J&J enters CAR-T field with $350M Legend deal – BioPharma Dive
PharmaTimes |
J&J enters CAR–T field with $350M Legend deal
BioPharma Dive Johnson & Johnson has bought itself a foothold in the accelerating CAR–T field, paying $350 million upfront through its subsidiary Janssen Biotech Inc. to gain access to a cancer cell therapy candidate developed by a previously little-known Chinese … Janssen buys into Legend's CART therapy Chinese biotech firm Genscript's shares jump by a third on US$350m Johnson & Johnson unit tie-up |
